Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects

Jeffrey C. Cleary, Yauel Karmazyn, Peter Mogayzel, Beth L Laube

Research output: Contribution to journalArticle

Abstract

Acute inhalations of β2-adrenergic receptor agonists increase mucociliary clearance (MCC). Less is known about the effect of long-term inhalations of these agents on MCC, or cough clearance (CC). We hypothesized that chronic inhalations of nebulized levalbuterol, the R-isomer of albuterol, would enhance MCC and/or CC in healthy subjects, compared to albuterol or placebo. This was a randomized, double-blind, placebo-controlled trial in ten healthy, adult subjects who inhaled nebulized levalbuterol (1.25 mg), albuterol (2.5 mg), or placebo for 7 days, three times daily. MCC and CC were measured 6-7 h after the last dose of drug on the 7th day of treatment. These were quantified from gamma camera images of the lungs following inhalation of an aerosol containing the isotope 99mtechnetium. Levalbuterol did not improve MCC or CC. MCC averaged (±SD) 12.3±8.3%, 9.2±4.7% and 10.0±9.6% with placebo, albuterol and levalbuterol, respectively. CC averaged 3.9±6.8%, 4.9±4.3% and 3.8±6.4% with placebo, albuterol and levalbuterol, respectively. These results indicate that chronic inhalations of nebulized levalbuterol for 1 week do not increase MCC or CC in healthy subjects, compared to albuterol or placebo.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume21
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Levalbuterol
Mucociliary Clearance
Albuterol
Inhalation
Cough
Healthy Volunteers
Placebos
Adrenergic Agonists
Gamma Cameras
Aerosols
Isotopes
Isomers
Cameras
Lung

Keywords

  • β-adrenergic receptor agonists
  • Aerosols
  • Mucociliary clearance

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. / Cleary, Jeffrey C.; Karmazyn, Yauel; Mogayzel, Peter; Laube, Beth L.

In: Pulmonary Pharmacology and Therapeutics, Vol. 21, No. 1, 02.2008, p. 105-111.

Research output: Contribution to journalArticle

@article{d2459a637f16421488c33891e3a590f7,
title = "Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects",
abstract = "Acute inhalations of β2-adrenergic receptor agonists increase mucociliary clearance (MCC). Less is known about the effect of long-term inhalations of these agents on MCC, or cough clearance (CC). We hypothesized that chronic inhalations of nebulized levalbuterol, the R-isomer of albuterol, would enhance MCC and/or CC in healthy subjects, compared to albuterol or placebo. This was a randomized, double-blind, placebo-controlled trial in ten healthy, adult subjects who inhaled nebulized levalbuterol (1.25 mg), albuterol (2.5 mg), or placebo for 7 days, three times daily. MCC and CC were measured 6-7 h after the last dose of drug on the 7th day of treatment. These were quantified from gamma camera images of the lungs following inhalation of an aerosol containing the isotope 99mtechnetium. Levalbuterol did not improve MCC or CC. MCC averaged (±SD) 12.3±8.3{\%}, 9.2±4.7{\%} and 10.0±9.6{\%} with placebo, albuterol and levalbuterol, respectively. CC averaged 3.9±6.8{\%}, 4.9±4.3{\%} and 3.8±6.4{\%} with placebo, albuterol and levalbuterol, respectively. These results indicate that chronic inhalations of nebulized levalbuterol for 1 week do not increase MCC or CC in healthy subjects, compared to albuterol or placebo.",
keywords = "β-adrenergic receptor agonists, Aerosols, Mucociliary clearance",
author = "Cleary, {Jeffrey C.} and Yauel Karmazyn and Peter Mogayzel and Laube, {Beth L}",
year = "2008",
month = "2",
doi = "10.1016/j.pupt.2007.01.002",
language = "English (US)",
volume = "21",
pages = "105--111",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects

AU - Cleary, Jeffrey C.

AU - Karmazyn, Yauel

AU - Mogayzel, Peter

AU - Laube, Beth L

PY - 2008/2

Y1 - 2008/2

N2 - Acute inhalations of β2-adrenergic receptor agonists increase mucociliary clearance (MCC). Less is known about the effect of long-term inhalations of these agents on MCC, or cough clearance (CC). We hypothesized that chronic inhalations of nebulized levalbuterol, the R-isomer of albuterol, would enhance MCC and/or CC in healthy subjects, compared to albuterol or placebo. This was a randomized, double-blind, placebo-controlled trial in ten healthy, adult subjects who inhaled nebulized levalbuterol (1.25 mg), albuterol (2.5 mg), or placebo for 7 days, three times daily. MCC and CC were measured 6-7 h after the last dose of drug on the 7th day of treatment. These were quantified from gamma camera images of the lungs following inhalation of an aerosol containing the isotope 99mtechnetium. Levalbuterol did not improve MCC or CC. MCC averaged (±SD) 12.3±8.3%, 9.2±4.7% and 10.0±9.6% with placebo, albuterol and levalbuterol, respectively. CC averaged 3.9±6.8%, 4.9±4.3% and 3.8±6.4% with placebo, albuterol and levalbuterol, respectively. These results indicate that chronic inhalations of nebulized levalbuterol for 1 week do not increase MCC or CC in healthy subjects, compared to albuterol or placebo.

AB - Acute inhalations of β2-adrenergic receptor agonists increase mucociliary clearance (MCC). Less is known about the effect of long-term inhalations of these agents on MCC, or cough clearance (CC). We hypothesized that chronic inhalations of nebulized levalbuterol, the R-isomer of albuterol, would enhance MCC and/or CC in healthy subjects, compared to albuterol or placebo. This was a randomized, double-blind, placebo-controlled trial in ten healthy, adult subjects who inhaled nebulized levalbuterol (1.25 mg), albuterol (2.5 mg), or placebo for 7 days, three times daily. MCC and CC were measured 6-7 h after the last dose of drug on the 7th day of treatment. These were quantified from gamma camera images of the lungs following inhalation of an aerosol containing the isotope 99mtechnetium. Levalbuterol did not improve MCC or CC. MCC averaged (±SD) 12.3±8.3%, 9.2±4.7% and 10.0±9.6% with placebo, albuterol and levalbuterol, respectively. CC averaged 3.9±6.8%, 4.9±4.3% and 3.8±6.4% with placebo, albuterol and levalbuterol, respectively. These results indicate that chronic inhalations of nebulized levalbuterol for 1 week do not increase MCC or CC in healthy subjects, compared to albuterol or placebo.

KW - β-adrenergic receptor agonists

KW - Aerosols

KW - Mucociliary clearance

UR - http://www.scopus.com/inward/record.url?scp=38049051018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049051018&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2007.01.002

DO - 10.1016/j.pupt.2007.01.002

M3 - Article

C2 - 17360209

AN - SCOPUS:38049051018

VL - 21

SP - 105

EP - 111

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 1

ER -